Chen-Feng Qi

Dr. Chen-Feng Qi


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2002
Verified
Journal Article
Closed access
GFGalina N Filippova
Galina N Filippova
CQChen-Feng Qi
Chen-Feng Qi
JUJonathan E Ulmer
Jonathan E Ulmer
JMJames M Moore
James M Moore
MWMichael D Ward
Michael D Ward
VLVictor Lobanenkov
Victor Lobanenkov

29 July 2008 in Immunologic Research
Verified
Journal Article
Closed access
PDF file
CQChen-Feng Qi
Chen-Feng Qi
ZLZhaoyang Li
Zhaoyang Li
MRMark Raffeld
Mark Raffeld
HWHongsheng Wang
Hongsheng Wang
AKAlexander L. Kovalchuk
Alexander L. Kovalchuk
HMHerbert C. Morse
Herbert C. Morse

Verified
Journal Article
Open access
PDF file
CQChen-Feng Qi
Chen-Feng Qi
YKYong-Soo Kim
Yong-Soo Kim
SXShao Xiang
Shao Xiang
ZAZiedulla Abdullaev
Ziedulla Abdullaev
TTTed A. Torrey
Ted A. Torrey
HIHerbert C. Morse Iii
Herbert C. Morse Iii
Transcriptional activation of MYC is a hallmark of many B cell lineage neoplasms. MYC provides a constitutive proliferative signal but can also initiate ARF-dependent activation of p53 and apoptosis. The E3 ubiquitin ligase, ARF-BP1, encoded by HUWE1, modulates the activity of both the MYC and the ARF-p53 signaling pathways, prompting us to determine if it is involved in the pathogenesis of MYC-driven B cell lymphomas. ARF-BP1 was expressed at high levels in cell lines from lymphomas with either wild type or mutated p53 but not in ARF-deficient cells. Downregulation of ARF-BP1 resulted in elevated steady state levels of p53, growth arrest and apoptosis. Co-immunoprecipitation studies identified a multiprotein complex comprised of ARF-BP1, ARF, p53, MYC and the multifunctional DNA-binding factor, CTCF, which is involved in the transcriptional regulation of MYC, p53 and ARF. ARF-BP1 bound and ubiquitylated CTCF leading to its proteasomal degradation. ARF-BP1 and CTCF thus appear to be key cofactors linking the MYC proliferative and p53-ARF apoptotic pathways. In addition, ARF-BP1 could be a therapeutic target for MYC-driven B lineage neoplasms, even if p53 is inactive, with inhibition reducing the transcriptional activity of MYC for its target genes and stabilizing the apoptosis-promoting activities of p53.

20 September 2013 in Leukemia Research
Verified
Journal Article
Closed access
CQChen-Feng Qi
Chen-Feng Qi
RZRuihua Zhang
Ruihua Zhang
JSJiafang Sun
Jiafang Sun
ZLZhaoyang Li
Zhaoyang Li
DSDong-Mi Shin
Dong-Mi Shin
HMHerbert C. Morse
Herbert C. Morse

25 November 2015 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
ESEmmanouil Saloustros
Emmanouil Saloustros
PSParaskevi Salpea
Paraskevi Salpea
CQChen-Feng Qi
Chen-Feng Qi
LGLina A. Gugliotti
Lina A. Gugliotti
KTKitman Tsang
Kitman Tsang
Constantine A. StratakisConstantine A. Stratakis
Constantine A. Stratakis
Protein kinase A (PKA) is a holoenzyme that consists of a dimer of regulatory subunits and two inactive catalytic subunits that bind to the regulatory subunit dimer. Four regulatory subunits (RIα, RIβ, RIIα, RIIβ) and four catalytic subunits (Cα, Cβ, Cγ, Prkx) have been described in the human and mouse genomes. Previous studies showed that complete inactivation of the Prkar1a subunit (coding for RIα) in the germline leads to embryonic lethality, while Prkar1a–deficient mice are viable and develop schwannomas, thyroid, and bone neoplasms, and rarely lymphomas and sarcomas. Mice with inactivation of the Prkar2a and Prkar2b genes (coding for RIIα and RIIβ, respectively) are also viable but have not been studied for their susceptibility to any tumors. Cohorts of Prkar1a +/− , Prkar2a +/− , Prkar2a −/− , Prkar2b +/− and wild type (WT) mice have been observed between 5 and 25 months of age for the development of hematologic malignancies. Tissues were studied by immunohistochemistry; tumor-specific markers were also used as indicated. Cell sorting and protein studies were also performed. Both Prkar2a −/− and Prkar2a +/− mice frequently developed hematopoietic neoplasms dominated by histiocytic sarcomas (HS) with rare diffuse large B cell lymphomas (DLBCL). Southern blot analysis confirmed that the tumors diagnosed histologically as DLBCL were clonal B cell neoplasms. Mice with other genotypes did not develop a significant number of similar neoplasms. Prkar2a deficiency predisposes to hematopoietic malignancies in vivo. RIIα’s likely association with HS and DLBCL was hitherto unrecognized and may lead to better understanding of these rare neoplasms.

6 February 2006 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
CLChang Hoon Lee
Chang Hoon Lee
MMMark Melchers
Mark Melchers
HWHongsheng Wang
Hongsheng Wang
TTTed A. Torrey
Ted A. Torrey
RSRebecca Slota
Rebecca Slota
HMHerbert C. Morse
Herbert C. Morse